Table 1. Triggers for mutational analysis: DASISION 3-year database.

On-treatment, clinically relevant events	Off-treatment, reason for discontinuation from study
No confirmed CCyR within 12 months	Disease progressiona
No MMR within 12 months	Maximum clinical benefitb
Fivefold increase in BCR-ABL1 transcript	Intolerance Treatment failure
levels with loss of MMR
Loss of CCyRc	Adverse event unrelated to study drug
	Withdrew consent
	Pregnancy
	Loss to follow-up
	Poor/noncompliance
	Subject request to discontinue

Abbreviations: CCyR, complete cytogenetic response; DASISION, Dasatinib versus Imatinib Study in Treatment-Naive CML-CP; MMR, major molecular response.

^aIncreasing white blood cell count, loss of complete hematologic response (CHR), loss of major cytogenetic response, transformation to accelerated phase/blast phase and death.

^bAny subject who received study therapy and then discontinued treatment for intolerance (recurrent ≥grade 3 hematologic toxicity or ≥grade 2 nonhematologic toxicity despite dose reduction necessitating discontinuation of therapy) or treatment failure (lack of hematologic response at 3 months, lack of CHR or CyR at 6 months, lack of partial cytogenetic response at 12 months and lack of CCyR at 18 months).

^cAs of last patient status; patients with interim loss of CCyR who subsequently regained a CCyR were not included.